Member Info for jint

I’ve asked,
Is protocol Version 7 likely to be published in the near future.

Doc & CW
Thank you, some pragmatic common sense spoken.

Apologies….graking

grading
“ Or is it bad news to date and which they have no option but to defer for as long as as humanly possible”

Why would this be the case when the Phase 3 trial is double blinded and ACTIV2 (also blinded) is not under their control.

Just a reminder to register to listen in, questions must be submitted 48hours beforehand.

Simple .... why would Synairgen want to entertain an offer now when they are on the cusp of outstanding Phase 3 trials.

I agree Kevin1977, there is no point, the checks and balances that have to go in publishing a RNS for news we already know is pointless. I prefer them getting on with the tasks in hand and I’ve no doubt there are many including the upcoming AGM.

GLA

Meelie:
For your information the two new Synairgen SGN001 patents were filed (priority date) on the 20th July and 21st July 2020 respectively.

The Patent Office Journal detailing these filings (priority date) was published on the 2nd September 2020, hence the RNS of the 9th September 2020.

So the wheels were put in motion as soon as the results of Phase2 were published.

Hope this helps.

GLA

Tornadotony : your chart analysis is always a welcome.

Apologies: Tonlin

Tonkin
You’ve obviously overlooked the worldwide Phase3 hospital trials that we as investors have financed.
This is where the big returns will come from in treating this current pandemic and pandemics of the future with stockpiling, check out the RNS business case.
ACTIV2 if successful is a nice to have bolt on but not an all or nothing.

From my understanding of the SGN001 patent. It has been broadened as far as possible (for the patent examiners to accept) within array for possible alternative non natural components that could be proved to work.

Of course progress can never be thwarted by over-arching patent claims that cannot be proved. It is possible a new formulation could be developed but I believe the SGN001 teams work over 15 years has culminated in the best in class for both 1a and 1b.
Good luck to any who try to surpass them!

The indisputable fact is Synairgen has granted patents in key markets for the SGN001 formulation and delivery method.

Hopefully the IP can be further enhanced by the recently filed applications of 20th and 21st July 2020.
Obviously at this present time we will not know there contents until publication which could be up to 18months from filing date.

gkb47
Hi, a filed PCT allows the company to file a patent application in each individual territory of their choosing in a given time period (30 months from original U.K. filing date).

A filed PCT does not give them a world patent (there is no such facility) it just allows extra time to file in chosen territories with the priority date that was first filed in the U.K. application.

Ghia:
Thank you for clarification re: total numbers for ACTIV2 phase 3

Kevinl1977
I believe they have to reach the 220 target for the phase 2 part of the ACTIV2 trial and then hopefully progress on to the phase 3 part (610 in total)
As far as I know the protocols for the ACTIV2 phase 3 are still to be announced.

Sparkyboy1:
I may have got the wrong end of the stick with your last post, but why are you selling SGN shares in your ISA to put in next years ISA ?
If they are SGN shares and you want them leave them there, from the 6th April you’ll have the capability of the new ISA allowance of £20k if you wish to add more.

Doc:
Exactly on point!

Axe
Thumbs up from me, good post.

Jaffjoon
Congratulations to you both, a very pleasant post to read, must get the Synairgen name thinking cap on :)